Search

everythinglearnresearchcommunity

for

Search:↓

A woman with advanced eye cancer went into complete remission using a combination of immunotherapy and topical treatments.

Tofacitinib effectively treated a woman's severe symptoms from a rare autoimmune condition.

Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.

Intensive immunosuppression can reduce relapse rates in multiple sclerosis patients, despite some side effects.

Belimumab effectively controls SLE disease activity and reduces steroid use.

Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.

JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.

Leflunomide may lower alopecia areata risk, while other immunomodulators might increase it.

Upadacitinib improved multiple immune-related conditions in one patient.

Tofacitinib can regrow hair in alopecia areata patients, but some may experience flares during treatment.

TAGX-0003 protected hair follicles and reversed alopecia areata in a mouse model.

Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.

A combination of ixekizumab and tofacitinib successfully treated severe scalp cellulitis, leading to hair regrowth.

ARQ-234, a protein designed to treat atopic dermatitis, shows increased effectiveness in early testing.

A patient with Crohn's disease grew back their hair after stopping Adalimumab, which had caused hair loss.

Eculizumab helps reduce blood transfusions and stabilize hemoglobin but increases infection risk and is expensive.

Upadacitinib effectively treated a patient with multiple inflammatory conditions.

Tofacitinib may be safe and effective for treating certain skin conditions in children.

Belimumab effectively reduces disease activity in lupus patients, regardless of initial serologic status.

Rituximab leads to longer remission and fewer side effects than cyclophosphamide.

Leflunomide may reduce the risk of alopecia areata, while methotrexate, cyclosporine, and rituximab may increase it.

Long-term Imiquimod treatment causes initial skin inflammation that lessens over time, and topical corticosteroids reduce this inflammation and cytokines in a mouse model of psoriasis.

A woman with severe hair loss was successfully treated with the drug adalimumab.

Tildrakizumab significantly improved recalcitrant lichen planopilaris and frontal fibrosing alopecia.

Tofacitinib effectively treated both ulcerative colitis and alopecia areata in two patients.

Ocrelizumab may cause pancreatitis in some patients.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

Upadacitinib improved both Crohn's ileitis and alopecia universalis in a patient.

Topical tofacitinib is a safe and effective treatment for autoimmune skin disorders.